Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban

Thromb Haemost. 2018 Jan;118(1):72-81. doi: 10.1160/TH17-02-0095. Epub 2018 Jan 5.

Abstract

Background: The prevalence of diabetes is growing, and diabetes is an independent risk factor for both atrial fibrillation (AF) and stroke. However, the relative effectiveness and safety of different oral anticoagulants for diabetic patients with non-valvular AF remain unclear. We aimed to compare thromboembolic events, bleeding and mortality in diabetic AF patients treated with rivaroxaban, dabigatran and warfarin.

Methods and results: Diabetic AF patients taking dabigatran (n = 322), rivaroxaban (n = 320) or warfarin (n = 1,899) were identified from the nationwide diabetes pay-for-performance program (n = 814,465) in Taiwan. Outcomes and comorbidities were evaluated by linking with Taiwan National Health Insurance Research Database. Propensity score weighting method was used to balance covariates across study groups. Patients were followed up until the first occurrence of any study outcome or the study end date. Compared with warfarin, dabigatran significantly decreased the risk of all-cause mortality (hazard ratio [HR] = 0.348, 95% confidence interval [CI] = 0.157-0.771) and gastrointestinal bleeding (HR = 0.558, 95% CI = 0.327-0.955). Relative effectiveness and safety outcomes between rivaroxaban and warfarin were comparable. Compared with rivaroxaban, dabigatran significantly decreased the risk of all-cause mortality (HR = 0.310, 95% CI = 0.121-0.798) and was associated with a borderline reduced risk for composite safety end points (HR = 0.670, 95% CI = 0.421-1.067).

Conclusion: In diabetic AF patients, dabigatran and rivaroxaban showed a superior or non-inferior effectiveness and safety profile compared with warfarin. Dabigatran was associated with a significantly lower risk of mortality than rivaroxaban.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Aged
  • Anticoagulants / administration & dosage
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / mortality
  • Cohort Studies
  • Comparative Effectiveness Research
  • Dabigatran / administration & dosage*
  • Databases, Factual
  • Diabetes Complications
  • Diabetes Mellitus* / mortality
  • Female
  • Humans
  • Male
  • Middle Aged
  • Patient Safety
  • Proportional Hazards Models
  • Risk
  • Risk Factors
  • Rivaroxaban / administration & dosage*
  • Stroke / complications
  • Stroke / mortality
  • Stroke / prevention & control*
  • Taiwan
  • Thromboembolism / etiology
  • Treatment Outcome
  • Warfarin / administration & dosage*

Substances

  • Anticoagulants
  • Warfarin
  • Rivaroxaban
  • Dabigatran